Redeye states that Catella delivered a quarter mostly in line with estimates, showing impressive cost control across the board. Redeye keeps its estimates largely intact, although reducing near-term estimates for Corporate Finance. Investment Management delivered solid numbers in a challenging environment, with intact AUM development q/q. Redeye raises its valuation range and continues to view the divestment of Kaktus as the most important catalyst for the share in the near term.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/